Accueil>>Signaling Pathways>> Others>> FAS>>FASN inhibitor 1

FASN inhibitor 1

Catalog No.GC33398

L'inhibiteur FASN 1 est un inhibiteur de la synthase d'acide gras (FASN) extrait du brevet US20170119786A1, composé 242A.

Products are for research use only. Not for human use. We do not sell to patients.

FASN inhibitor 1 Chemical Structure

Cas No.: 2097262-60-5

Taille Prix Stock Qté
5mg
315,00 $US
En stock
10mg
522,00 $US
En stock
25mg
990,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

FASN inhibitor 1 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A.

Human PBMC and monocytes in cell cultures are stimulated with lipopolysaccharide (LPS), a Toll 4 receptor agonist, or lipoteichoic acid (LTA), a Toll 2 receptor agonist. Stimulation with either LPS or LTA plus DMSO, the solvent for FASN inhibitor 1 (Compound 242A), results in secretion of IL-1 beta. FASN inhibitor 1 treatment of PBMC, which is a mixed population of mononuclear cells including both lymphocytes and monocytes, reduces the level of IL-1 beta resulting from either LPS or LTA stimulation. For monocytes, FASN inhibitor 1 treatment reduces the level of IL-1 beta resulting from LTA stimulation whereas there is only a slight reduction after LPS stimulation[1].

[1]. Buckley, Douglas I, et al. HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS. US20170119786A1

Avis

Review for FASN inhibitor 1

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for FASN inhibitor 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.